Webinar: Dissecting Immune Phenotypes with Multiplex Immunohistochemistry to Optimize Drug Development

SUMMARY

As targeted molecular therapies have become pivotal in the management of patients with complex diseases, the essential requirement for biomarkers has become even more intense, with response rates maintained in the 20%–30% range. Moreover, the list of treatment alternatives, including combination therapies, is rapidly evolving. The molecular profiling and specific disease-associated immune contexture may be predictive of response or resistance to these therapeutic strategies.

In collaboration with Fluidigm, as part of their ‘Scientist in the Spotlight’ webinar series, Dr. Corinne Ramos from ImaBiotech discussed the use of Fluidigm’s Hyperion (Imaging Mass Cytometry) platform, combined with image analysis in identifying specific proteins, determining the spatial distribution of immune cells to investigate immune evasion mechanisms and discovering potential biomarkers to assess mechanisms of action and predict response to a given treatment. This webinar highlighted the advantage of using such high multiplex immunohistochemistry platform in routine analysis to obtain faster throughput in a GLP environment.

THURSDAY, NOVEMBER 4TH 2021

  • EUROPE TIME: 4PM CET
  • USA TIME: 11AM EST

Conference animated by :




Search news